A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 06 Apr 2025
At a glance
- Drugs CM 336 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors KeyMed Biosciences
Most Recent Events
- 26 Mar 2025 According to KeyMed Biosciences media release, as of the date, company continuously proceeded and the CM-336 is currently in the dose-expansion phase of Phase I/II clinical study.
- 04 Apr 2022 According to KeyMed Biosciences media release, CM336 has been approved by the National Medical Products Administration (NMPA) for the treatment of relapsed or refractory patients.
- 01 Apr 2022 New trial record